Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary

Szabó, Bálint Gergely; Lenart, Katalin Szidonia; Petrik, Borisz; Gáspár, Zsófia; Kiss-Dala, Noemi; Szlávik, János; Vályi‐Nagy, István; Lakatos, Botond

doi:10.1007/s11357-021-00452-9

Cited by 8 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Favipiravir treatment did not show a statistically significant difference in disease progression between the cohorts of moderate-to-severe COVID-19 patients. Moreover, the patients in the favipiravir cohort needed immunomodulatory therapy more often than the patients in the non-favipiravir cohort [ 21 ].…”

Section: Resultsmentioning

confidence: 99%

Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?

et al. 2022

View full text Add to dashboard Cite

Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 years or older are more prone to develop severe illness. We aim to provide a short summary of the current knowledge of the antiviral efficacy of favipiravir with respect to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–infected elderly patients. We found that it is rather controversial whether favipiravir is effective against SARS-CoV-2 infection. Data regarding patients 65 years or older is not sufficient to support or reject the usage of favipiravir for COVD-19 treatment. Further studies would be advisable to elicit the efficiency of favipiravir in elderly COVID-19 patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, in Hungary, favipiravir had been included in the national COVID-19 guideline based on an off-label approval by the National Institute of Pharmacy and Nutrition. Subsequent trials, however, did not con rm its positive effect on clinical outcomes in the early phase of COVID-19 [9,10].…”

Section: Current Literaturementioning

confidence: 95%

Outcomes of high-risk adult outpatients with haematological malignancies treated with early remdesivir therapy during the SARS-CoV-2 omicron era: experiences from the national centre of Hungary

Gáspár¹,

Szabó²,

Ábrahám³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Objectives Emerging evidence suggests that remdesivir might improve clinical outcome of high-risk outpatients with COVID-19. Our aim was to evaluate characteristics and outcomes of non-hospitalized adults with haematological malignancies diagnosed with COVID-19 and treated with early remdesivir therapy during the omicron wave. Methods A single-centre prospective cohort study was performed among adult patients between February–June 2022, during the circulation of PANGO subvariants BA.2, BA.4 and BA.5 in Hungary. Patients were enrolled based on pre-defined criteria. Clinical characteristics (demography, comorbidities, vaccination status, imaging, treatment, and disease course) and outcomes (COVID-19 related hospitalisation, oxygen supplementation, intensive care support, all-cause death) were assessed at 28-days post-treatment. Results Altogether 127 patients were enrolled: 51.2% (65/127) were female with a median age of 59 ± 22 (21‒92) years, and 48.8% (62/127) had active haematological malignancy. At 28-days post-treatment, 7.1% (9/127) of patients required COVID-19 related hospitalisation, 2,4% (3/127) required oxygen supplementation, 1,6% (2/127) required intensive care, and 0.8% (1/127) died due to a non-COVID-19 related secondary infection at the intensive care unit, all with haematological malignancies. Conclusion Early remdesivir treatment might be a feasible strategy among high-risk outpatients with haematological malignancies and COVID-19 during the omicron wave.

show abstract

“…However, the results of trials of FVP have been mixed. For example, a prospective, sequential cohort study recently conducted by Szabo et al 117…”

Section: Fvp (T-705) An Orally Bioavailable Prodrug Was Initially App...mentioning

confidence: 99%

Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges

Wang

Yang

2021

Journal of Medical Virology

View full text Add to dashboard Cite

In this era, broad‐spectrum prodrugs with anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) activities are gaining considerable attention owing to their potential clinical benefits and role in combating the fast‐spreading coronavirus disease 2019 (COVID‐19) pandemic. The last 2 years have seen a surge of reports on various broad‐spectrum prodrugs against SARS‐CoV‐2, and in in vitro studies, animal models, and clinical practice. Currently, only remdesivir (with many controversies and limitations) has been approved by the U.S. FDA for the treatment of SARS‐CoV‐2 infection, and additional potent anti‐SARS‐CoV‐2 drugs are urgently required to enrich the defense arsenals. The world has ubiquitously grappled with the COVID‐19 pandemic, and the availability of broad‐spectrum prodrugs provides great hope for us to subdue this global threat. This article reviews promising treatment strategies, antiviral mechanisms, potential benefits, and daunting clinical challenges of anti‐SARS‐CoV‐2 agents to provide some important guidance for future clinical treatment.

show abstract

Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary

Cited by 8 publications

References 16 publications

Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?

Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?

Outcomes of high-risk adult outpatients with haematological malignancies treated with early remdesivir therapy during the SARS-CoV-2 omicron era: experiences from the national centre of Hungary

Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges

Contact Info

Product

Resources

About